Arena Pharmaceuticals (Arena Pharmaceuticals) Total Inventories : $0.00 Mil (As of Dec. 2021)

View and export this data going back to 2000. Start your Free Trial

What is Arena Pharmaceuticals Total Inventories?

Arena Pharmaceuticals's total inventories for the quarter that ended in Dec. 2021 was $0.00 Mil. Arena Pharmaceuticals's average total inventories from the quarter that ended in Sep. 2021 to the quarter that ended in Dec. 2021 was $0.00 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Arena Pharmaceuticals's Net-Net Working Capital per share for the quarter that ended in Dec. 2021 was $7.13.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Arena Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Dec. 2021 was 0.00.

Arena Pharmaceuticals Total Inventories Historical Data

The historical data trend for Arena Pharmaceuticals's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arena Pharmaceuticals Total Inventories Chart

Arena Pharmaceuticals Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Total Inventories

Get a 7-Day Free Trial

Arena Pharmaceuticals Quarterly Data
	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21
Total Inventories	Get a 7-Day Free Trial															-	-	-	-	-

Arena Pharmaceuticals Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Arena Pharmaceuticals (NAS:ARNA) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Arena Pharmaceuticals's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2021 is

	Net-Net Working Capital Per Share (Q: Dec. 2021 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(550.469	+	0.75 * 0	+	0.5 * 0	-	111.468
-	0	-	0)	/	61.5641
=	7.13

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Arena Pharmaceuticals's Days Inventory for the three months ended in Dec. 2021 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Dec. 2021 )	/	Cost of Goods Sold (Q: Dec. 2021 )	*	Days in Period
	=	0	/	0	*	365 / 4
	=

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Arena Pharmaceuticals's Inventory Turnover for the quarter that ended in Dec. 2021 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Dec. 2021 )	/	Average Total Inventories (Q: Dec. 2021 )
	=	0	/	0
	=	N/A

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Arena Pharmaceuticals's Inventory to Revenue for the quarter that ended in Dec. 2021 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Dec. 2021 )	/	Revenue (Q: Dec. 2021 )
	=	0	/	0.054
	=	0.00

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Arena Pharmaceuticals Total Inventories Related Terms

Thank you for viewing the detailed overview of Arena Pharmaceuticals's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Arena Pharmaceuticals (Arena Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arena Pharmaceuticals Inc (NAS:ARNA) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

N/A

Address

136 Heber Avenue, Suite 204, Park City, UT, USA, 84060

Website

https://www.arenapharm.com

Arena Pharmaceuticals is a biotechnology company targeting G-protein-coupled receptors. The company has one internally discovered drug, lorcaserin, which has been approved and is marketed in the U.S. and South Korea to target weight management. It is commercialized under the brand name Belviq. The company is collaborating with Eisai to market Belviq in other countries. It has a presence in Europe through its Swiss subsidiary, Arena GmbH. The company's pipeline contains drugs targeting autoimmune diseases, vascular diseases, thrombotic diseases, dementia-associated psychosis, nervous system issues, and pain.

Executives

Amit Munshi	director, officer: President and CEO	C/O EPIRUS BIOPHARMACEUTICALS, INC., 699 BOYLSTON STREET, 8TH FLOOR, BOSTON MA 02116
Robert Lisicki	officer: EVP, Chief Commercial Officer	C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Dallas Jayson Donald Alexander	director	AIMMUNE THERAPEUTICS, INC., 8000 MARINA BOULEVARD, SUITE 300, BRISBANE CA 94005
Vincent Aurentz	officer: Executive VP and CBO	C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Tina Susan Nova	director	C/O ARENA PHARMACEUTICALS, INC., 6166 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Christopher Cabell	officer: EVP, Head of R&D, and CMO	C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Manmeet Singh Soni	director	C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE, SUNNYVALE CA 94085
Kieran Gallahue	director	PO BOX 684369, PARK CITY UT 84068
Katharine Knobil	director	C/O KALEIDO BIOSCIENCES, INC., 65 HAYDEN AVE., LEXINGTON MA 02421
Jennifer Jarrett	director	C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Garry Arthur Neil	director	555 CALIFORNIA STREET, SUITE 365, SAN FRANCISCO CA 94104
Oliver Fetzer	director	AUXILIUM PHARMACEUTICALS, INC., 40 VALLEY STREAM PARKWAY, MALVERN PA 19355
Laurie Stelzer	officer: EVP & Chief Financial Officer	6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Joan Schmidt	officer: EVP, General Counsel & Sec	C/O ARENA PHARMACEUTICALS, INC. 6154 NANCY RIDGE DRIVE SAN DIEGO CA 92121
Kevin Robert Lind	officer: Executive VP and CFO	C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121